Get started
Author

Lina Gu

ORCID: 0000-0001-8599-6238
Observed ORCID: 0000-0001-8599-6238
OpenAlex ID: A5044904573
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP -Deleted Cancers
2024 · Kevin M. Cottrell, Kimberly J. Briggs, et al. · Journal of Medicinal Chemistry · 91
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2022 · Antoine Simoneau, Justin L. Engel, et al. · Molecular Cancer Therapeutics · 86
Abstract 3941: TNG908 is an MTAPnull-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies
2022 · Kimberly J. Briggs, Kevin M. Cottrell, et al. · Cancer Research · 9
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
2025 · Scott Throner, Tianshu Feng, et al. · Bioorganic & Medicinal Chemistry Letters · 1
Supplementary Tables from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2023 · Antoine Simoneau, Justin L. Engel, et al. · 1
Supplementary Data from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2023 · Antoine Simoneau, Justin L. Engel, et al. · 1
Supplementary Figure S2 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S5 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S6 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S6 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S8 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S7 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S4 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S8 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S5 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S2 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S7 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Data from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S3 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S3 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S4 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al. · Cancer Research
Supplementary Figure S1 from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2025 · Antoine Simoneau, Justin L. Engel, et al.
PDF
Works count: 40
Citation count: 189
H-index: 3
I10-index: 2
Year
Topic
Type